TrialThe Lancet. Oncology2018

Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study.

Wen-Zhao Zhong et al.PubMed ↗Publisher ↗

No numbers read from the abstract.